UniDoc Successfully Concludes Pilot Trials with OnPharm-United

–OnPharm-United requests to move project to contract

VANCOUVER, BC, August 31, 2022 (GLOBE NEWSWIRE) – UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF) (“UniDoc,” or the “Company”), an innovator in the telehealth sector, is pleased to announce it has successfully concluded a series of pilot trials with OnPharm-United, a network of independent pharmacies in Canada.

As previously announced (March 9, 2022), pursuant to a letter of intent (the “LOI”) of October 8, 2021, UniDoc and OnPharm-United agreed to jointly offer a health care and virtual care platform solution exclusively to the entire OnPharm-United network in Ontario subject to the successful testing of UniDoc’s Virtual Care Solutions Model. These tests have now concluded satisfactorily and OnPharm-United has indicated it is ready to progress to contract UniDoc’s services including development of roll-out details, locations, and timelines to its network of pharmacies throughout Ontario.

Dr. Chad Burkhart, UniDoc’s Telemedicine advisor states: “The OnPharm-United pilot tests were a resounding success. As an active professional participant in the test, not only was I able to undertake patient visits remotely, but I was also able to easily use the available diagnostic tools and was further able to process and transact the standard rate services fees with OHIP for the visit. In my mind, this validates our entire process from both the patient and the provider prospective.”

OnPharm-United was founded by independent pharmacy owners, for independent pharmacy owners. The board members and executives of the organization operate independent pharmacies and understand the needs, challenges, and opportunities of their over 600 independent pharmacy members across Ontario.

As part of the proposed service contract, UniDoc intends to enter into a business agreement with OnPharm-United as soon as commercially possible, the details of which will be announced upon execution of the proposed contract. UniDoc, as part of the LOI has agreed to provide a variety of equipment and installation supervision, software installation and training services.

UniDoc CEO Antonio Baldassarre comments, “Today’s announcement is a significant achievement for everyone involved with our growing venture. Acceptance by OnPharm-United is an important validation of our concept and launches us directly into an important segment of the domestic healthcare sector. We are extremely pleased that the test was a success and look forward to working with the OnPharm-United team to finalize the next steps and advance our transition from a domestic development phase into active operations in one of the busiest marketplaces in Canada.”

On Behalf of the Board of Directors,

Sincerely,

~Antonio Baldassarre~

Antonio Baldassarre

CEO, President & Director

UniDoc Health Corp.

About OnPharm-United

OnPharm-United was created by OnPharm Inc. and United Pharma Group in October 2018 by bringing together two of the fastest growing networks for independent pharmacies in Canada. OnPharm-United includes over 600 members in Ontario. OnPharm-United provides its members with the ability to maintain their independent status while benefiting from a suite of innovative programs, services and resources to support their business and practice. For more information visit: www.onpharmunited.ca.

About UniDoc Health Corp. (CSE: UDOC) (FRA: L7T) (OTCQB: UDOCF)

UniDoc is developing a telehealth solution which is being designed as a self-contained remote virtual clinic within a private kiosk for patients to undergo full consultations as if they were present in a physician’s office. Telehealth opens the doors to a large segment of the population challenged by access, experience or understanding of online computer technology. It is the Company’s belief that physical accessibility is the key to its business proposition. UniDoc is dedicated to unlocking shareholder value by delivering an excellent product and sophisticated commercial network within an expedited timeframe. The UniDoc team encourages engagement, questions, and interest, so please stay in touch and invite anyone who might be interested in our story to visit our website at www.unidoctor.com and signup to receive the latest information with updates on our activities, events and progress. You are also invited to join us on social media with Facebook, Twitter or Instagram.

For further information, please contact

UniDoc Investor Relations

Tel: +1 778.383.6731

Email: info@unidoctor.com

Matt Chatterton, Director

Tel: +1 778.613.2082

Email: matt@unidoctor.com

Media Inquiries

media@unidoctor.com

Forward-Looking Statements

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, the entry into a service contract with OnPharm-United and the terms thereof, the provision by UniDoc of equipment and installation supervision, software installation and training services to OnPharm-United and the transition of the Company from a domestic development phase into active operations.

Forward-looking information is based on the assumptions, estimates, analysis, and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; the Company’s ability to secure additional financing on reasonable terms; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s  final prospectus dated December 2, 2021 under the heading “Risks Factors.” Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Sign Up For News Alerts

Enter your details below and we will add you to our News Alerts list.

Consent(Required)

Roberto Caon

Advisor

Mr. Caon is an elected member of the Italian Parliament. Since 2013, he has been a Member of the Italian Republic with the functions of: member of the Transport, Digitization, and Communications Commission of the Italian Parliament, member of the Bicameral Commission for Regional Affairs, and member of the Agriculture Commission. In Parliament, counted among his numerous successes, he has assisted with the implementation of various telemedicine services in the family sector. He has done this through the identification of innovative processes for patient care and the strengthening of multi-professional and multidisciplinary collaboration between different professionals. This work is now included in the proposed National Recovery and Resilience Plan, the 750 billion European plan that the member countries will use for the recovery of national economies, severely tested by the effects of the Covid-19 pandemic.

 

Prior to his current role in the Italian Parliament, Mr. Caon has spent over 30 years as an entrepreneur coordinating and designing solutions and technologies in the engineering, automotive and manufacturing sectors that are currently employed in 34 countries and used by hundreds of companies in both B2B and B2B2C environments. He held the role of owner and administrator of Giorgia Srl., a small / medium company active in the automotive and manufacturing engineering sector. He has worked extensively in the development of foreign markets for various companies in the metalworking and manufacturing sectors. He is currently a member of many trade associations linked to his extensive personal entrepreneurial background.

Austin Thornberry

Director

Mr. Thornberry is a seasoned finance professional with a background in advising start-up companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the technology and innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. He obtained his bachelor of commerce at McGill University and has held the CPA, CA, designation since 2019.

Matt Chatterton

DIRECTOR

Mr. Chatterton brings over 15 years of experience in development and execution of complex projects. His expertise includes project management, facility management, logistics, supply side processes and procedures at several operations in Canada and internationally. He has been involved in the public markets for the last three years managing initial public offering processes and transitioning businesses to postlisting operations. Mr. Chatterton is a professional engineer and graduate of Canada’s Queens University with a master’s degree in chemical process engineering (2003).

Sina Pirooz

Director

Mr. Pirooz is a registered and practicing pharmacist, and has been a professional member of the College of Pharmacists of British Columbia since 2003, with over 20 years of pharmaceuticals and pharmacy management experience. As owner of a compounding pharmacy, Mr. Pirooz has been dispensing pharmaceuticals for over 18 years and provides pharmacist and pharmacy management services to many of Canada’s largest pharmacy chains and drug stores. Mr. Pirooz is also the CEO and a director of Genix Pharmaceuticals Corporation, a company listed for trading on the TSXV.

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.

Jacob Moshinsky

Chief Operating Officer

Jacob is the CEO & founder of MoviWear a GPS, fall down detection & remote vital-sign monitoring platform, alerting caregivers of real-time emergencies. Jacob is a communications and technology expert with over 15 years’ experience in the field. the NurtureWatch health monitoring Smartwatch and MoviWearMED remote vital sign monitoring platform Prior to MoviWear, Jacob worked in both the Canadian telecom and the CPG industry. He led the Product Development and Business Strategy team at TELUS for the Small Business Portfolio. Jacob also worked in various product and service management roles within Rogers Communications where he launched and managed wireless and wireline products.

Antonio Baldassarre

CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels. Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value. Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino

Chairman of the Board of Directors

Mr. Franco Staino is the Developer of the Italian National anti-counterfeiting Program for Pharmaceuticals developed in conjunction with the Ministry of Health as well as the National Certification Program for all unsold Prescription Drugs in Partnership with Pharmindustria (National association of all Pharmaceutical Manufactures) through ASSINDE.

Through one of his Companies, Carlucci are responsible for the control, labelling and collection of all pharmaceutical prescription drugs in Italy, under the PHG umbrella Franco opened first a UK division, now has also expanded into 4 African countries. Over the Years Franco has been a Board Member and Contributor on various International Committees, including the United Nations.